Covid Positive | Covid negative | Percent with feature | Percent COVID positive | Hazards ratio | 95% CI | P | Comments | ||
ALL PATIENTS | |||||||||
Sarcoidosis | 13 | 1603 | 1616 | 0.80% | |||||
Sarc patients | |||||||||
Male | 2 | 275 | 277 | 14.11% | 0.72% | 0.4545 | 0.1003-2.0624 | >0.10 | |
Female | 10 | 620 | 630 | 32.09% | 1.59% | 709 no sex indicated | |||
Black | 3 | 90 | 93 | 4.89% | 3.23% | 2.817 | 0.7764-10.2227 | >0.10 | |
White | 9 | 777 | 786 | 41.30% | 1.15% | 826 patients biracial | |||
Roommate with COVID | |||||||||
yes | 2 | 3 | 5 | 0.25% | 40.00% | 58.5818 | 17.2179-1999.317 | <0.0001 | |
no | 11 | 1600 | 1611 | 82.07% | 0.68% | ||||
Health care provider | |||||||||
Yes | 1 | 82 | 83 | 4.23% | 1.20% | 1.5392 | 0.2025-11.6963 | >0.10 | |
no | 12 | 1521 | 1533 | 78.09% | 0.78% | ||||
Current meds * | If no response, assume | ||||||||
Prednisone | 5 | 318 | 323 | 16.38% | 1.55% | 2.5019 | 0.824-7.5971 | >0.10 | drug not used |
No prednisone | 8 | 1285 | 1293 | 65.57% | 0.62% | ||||
Plaquenil | 0 | 115 | 115 | 5.83% | 0.00% | 0.4572 | 0.02735-7.6429 | >0.10 | |
No plaquenil | 13 | 1418 | 1431 | 72.57% | 0.91% | ||||
anti-TNF | 1 | 115 | 116 | 5.88% | 0.86% | 1.0273 | 0.1348-7.8316 | >0.10 | |
no anti- TNF | 12 | 1418 | 1430 | 72.52% | 0.84% | ||||
Cytotoxic | 2 | 272 | 274 | 13.89% | 0.73% | 0.8905 | 0.1985-3.9952 | >0.10 | |
No cytotoxic | 11 | 1331 | 1342 | 68.05% | 0.82% | ||||
Rituximab | 1 | 10 | 11 | 0.56% | 9.09% | 12.1515 | 1.7255-85.5785 | 0.0122 | |
No rituximab | 12 | 1592 | 1604 | 81.34% | 0.75% | ||||
Underlying | |||||||||
COPD | 3 | 177 | 180 | 9.13% | 1.67% | 2.3933 | 0.6648-8.6150 | >0.10 | |
10 | 1426 | 1436 | 72.82% | 0.70% | |||||
1616 | |||||||||
Diabetes | 1 | 134 | 135 | 6.85% | 0.74% | 0.9142 | 0.1198-6.9776 | >0.10 | |
12 | 1469 | 1481 | 75.10% | 0.81% | |||||
1616 | |||||||||
Heart disease | 1 | 116 | 117 | 5.93% | 0.85% | 1.067 | 0.14-8.1402 | >0.10 | |
12 | 1487 | 1499 | 76.01% | 0.80% | |||||
1616 | |||||||||
Hypertension | 4 | 275 | 279 | 14.15% | 1.43% | 2.1298 | 0.6605-6.8673 | >0.10 | |
9 | 1328 | 1337 | 67.80% | 0.67% | |||||
1616 | |||||||||
Organ involved* | If no response, assume | ||||||||
Lung | 10 | 728 | 738 | 37.42% | 1.36% | 3.9657 | 1.0954-14.3563 | 0.0358 | not involved |
3 | 875 | 878 | 44.52% | 0.34% | |||||
1616 | |||||||||
Cardiac sarc | 1 | 12 | 13 | 0.66% | 7.69% | 9.4551 | 1.3244-67.5027 | 0.0251 | |
12 | 1463 | 1475 | 74.80% | 0.81% | |||||
1488 | |||||||||
Neuro sarc | 4 | 84 | 88 | 4.46% | 4.55% | 7.7172 | 2.424-24.5693 | 0.0005 | |
9 | 1519 | 1528 | 77.48% | 0.59% | |||||
1616 | |||||||||
Origin | |||||||||
US | NA | NA | 0 | 0.00% | #VALUE! | NOT AVAILABLE | |||
non US | NA | NA | 0 | 0.00% | #VALUE! | ||||
0 | |||||||||
Sarcoid age | |||||||||
Covid Positive | 54.4 ± 11.29 years | >0.10 | |||||||
Covid negative | 56.6 ± 10.39 years | ||||||||
Sarc ≥ 5 yr | 8 | 720 | 728 | 38.14% | 1.10% | 0.5357 | 0.163-1.7602 | >0.01 | Information missing on 986 patients |
Sarc < 5 yr | 4 | 191 | 195 | 10.21% | 2.05% | ||||
COVID outcome | Home | Hospital | ICU | Vent | |||||
Sarc | 8 | 3 | 0 | 0 | 2 no information | ||||
#REF! | |||||||||
COVID positive | Home | Hospital | If in hospital, considered | ||||||
Prednisone | bad outcome | ||||||||
Yes | 3 | 1 | 4 | 6.06% | 75.00% | 1.05 | 0.5037-2.1889 | >0.10 | Hazard ration for |
No | 5 | 2 | 7 | 10.61% | 71.43% | Hospitalization | |||
Infliximab | |||||||||
Yes | 0 | 0 | 0 | 0.00% | 0.00% | 0.7059 | 0.09617-5.1812 | >0.10 | |
No | 8 | 3 | 11 | 16.67% | 72.73% | ||||
Plaquenil | |||||||||
Yes | 0 | 0 | 0 | 0.00% | 0.00% | 0.7059 | 0.09617-5.1812 | >0.10 | |
No | 8 | 3 | 11 | 16.67% | 72.73% | ||||
Cytotoxic | |||||||||
Yes | 1 | 0 | 1 | 1.52% | 100.00% | 1.4286 | 0.9512-2.1435 | 0.0849 | |
No | 7 | 3 | 10 | 15.15% | 70.00% | ||||
Rituximab | |||||||||
Yes | 0 | 1 | 1 | 1.52% | 0.00% | 0.3235 | 0.02872-3.6449 | >0.10 | |
No | 8 | 2 | 10 | 15.15% | 80.00% | ||||